Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.

Gomes B, Driessens G, Bartlett D, Cai D, Cauwenberghs S, Crosignani S, Dalvie D, Denies S, Dillon CP, Fantin VR, Guo J, Letellier MC, Li W, Maegley K, Marillier R, Miller N, Pirson R, Rabolli V, Ray C, Streiner N, Torti VR, Tsaparikos K, Van den Eynde BJ, Wythes M, Yao LC, Zheng X, Tumang J, Kraus M.

Mol Cancer Ther. 2018 Dec;17(12):2530-2542. doi: 10.1158/1535-7163.MCT-17-1104. Epub 2018 Sep 19.

PMID:
30232146
2.

Deciphering tumor growth by clonal analysis.

Driessens G.

Crit Rev Oncog. 2014;19(5):317-25. Review.

PMID:
25404147
3.

SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma.

Boumahdi S, Driessens G, Lapouge G, Rorive S, Nassar D, Le Mercier M, Delatte B, Caauwe A, Lenglez S, Nkusi E, Brohée S, Salmon I, Dubois C, del Marmol V, Fuks F, Beck B, Blanpain C.

Nature. 2014 Jul 10;511(7508):246-50. doi: 10.1038/nature13305. Epub 2014 Jun 8.

PMID:
24909994
4.

Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction.

Locke FL, Zha YY, Zheng Y, Driessens G, Gajewski TF.

J Immunol. 2013 Aug 15;191(4):1677-85. doi: 10.4049/jimmunol.1202018. Epub 2013 Jul 12.

5.

Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo.

Zheng Y, Zha Y, Driessens G, Locke F, Gajewski TF.

J Exp Med. 2012 Nov 19;209(12):2157-63. doi: 10.1084/jem.20120342. Epub 2012 Nov 5.

6.

Defining the mode of tumour growth by clonal analysis.

Driessens G, Beck B, Caauwe A, Simons BD, Blanpain C.

Nature. 2012 Aug 23;488(7412):527-30. doi: 10.1038/nature11344.

7.

A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours.

Beck B, Driessens G, Goossens S, Youssef KK, Kuchnio A, Caauwe A, Sotiropoulou PA, Loges S, Lapouge G, Candi A, Mascre G, Drogat B, Dekoninck S, Haigh JJ, Carmeliet P, Blanpain C.

Nature. 2011 Oct 19;478(7369):399-403. doi: 10.1038/nature10525.

PMID:
22012397
8.

Long live sox2: sox2 lasts a lifetime.

Driessens G, Blanpain C.

Cell Stem Cell. 2011 Oct 4;9(4):283-4. doi: 10.1016/j.stem.2011.09.007.

9.

Beta-catenin inhibits T cell activation by selective interference with linker for activation of T cells-phospholipase C-γ1 phosphorylation.

Driessens G, Zheng Y, Locke F, Cannon JL, Gounari F, Gajewski TF.

J Immunol. 2011 Jan 15;186(2):784-90. doi: 10.4049/jimmunol.1001562. Epub 2010 Dec 13.

10.

Development of a successful antitumor therapeutic model combining in vivo dendritic cell vaccination with tumor irradiation and intratumoral GM-CSF delivery.

Driessens G, Nuttin L, Gras A, Maetens J, Mievis S, Schoore M, Velu T, Tenenbaum L, Préat V, Bruyns C.

Cancer Immunol Immunother. 2011 Feb;60(2):273-81. doi: 10.1007/s00262-010-0941-y. Epub 2010 Nov 13.

PMID:
21076828
11.

Beta-catenin does not regulate memory T cell phenotype.

Driessens G, Zheng Y, Gajewski TF.

Nat Med. 2010 May;16(5):513-4; author reply 514-5. doi: 10.1038/nm0510-513. No abstract available.

PMID:
20448567
12.

A designer ligand specific for Kv1.3 channels from a scorpion neurotoxin-based library.

Takacs Z, Toups M, Kollewe A, Johnson E, Cuello LG, Driessens G, Biancalana M, Koide A, Ponte CG, Perozo E, Gajewski TF, Suarez-Kurtz G, Koide S, Goldstein SA.

Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22211-6. doi: 10.1073/pnas.0910123106. Epub 2009 Dec 10.

13.

Costimulatory and coinhibitory receptors in anti-tumor immunity.

Driessens G, Kline J, Gajewski TF.

Immunol Rev. 2009 May;229(1):126-44. doi: 10.1111/j.1600-065X.2009.00771.x. Review.

14.

Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma.

Driessens G, Hoffmann P, Pouwels M, Zlotta A, Schulman C, Velu T, Bruyns CA.

J Immunother. 2009 Feb-Mar;32(2):140-4. doi: 10.1097/CJI.0b013e3181920275.

PMID:
19238012
15.

Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells.

Cham CM, Driessens G, O'Keefe JP, Gajewski TF.

Eur J Immunol. 2008 Sep;38(9):2438-50. doi: 10.1002/eji.200838289.

16.

Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8+ T cell recruitment and low relative regulatory T cell infiltration.

Driessens G, Gordower L, Nuttin L, Stordeur P, Blocklet D, Egrise D, Velu T, Bruyns C.

Cancer Immunol Immunother. 2008 Dec;57(12):1745-56. doi: 10.1007/s00262-008-0500-y. Epub 2008 Mar 28.

PMID:
18369621
17.

15-Deoxy-12,14-prostaglandin J2 inhibits interferon gamma induced MHC class II but not class I expression on ARPE cells through a PPAR gamma independent mechanism.

Willermain F, Dulku S, Gonzalez NS, Blero D, Driessens G, De Graef C, Caspers L, Bruyns C.

Prostaglandins Other Lipid Mediat. 2006 Sep;80(3-4):136-43. Epub 2006 Jul 14.

PMID:
16939878
18.
19.

Assessment of in vivo chemotherapy-induced DNA damage in a p53-mutated rat tumor by micronuclei assay.

Driessens G, Harsan L, Browaeys P, Giannakopoulos X, Velu T, Bruyns C.

Ann N Y Acad Sci. 2003 Dec;1010:775-9.

PMID:
15033826
20.

Micronuclei to detect in vivo chemotherapy damage in a p53 mutated solid tumour.

Driessens G, Harsan L, Robaye B, Waroquier D, Browaeys P, Giannakopoulos X, Velu T, Bruyns C.

Br J Cancer. 2003 Aug 18;89(4):727-9.

Supplemental Content

Loading ...
Support Center